

Muscarinic Modulation: An Emerging Therapeutic Opportunity in Psychiatry

Please Join Us for a Non-CME Industry Satellite Symposium (ISS03),
Financially Supported by Bristol Myers Squibb
During the 39th ECNP Congress

This program will explore the role of the cholinergic system in the etiology and treatment of schizophrenia, bipolar disorder, and Alzheimer's disease. The session will explore the evolving treatment landscapes and include discussion of current and emerging therapies and the therapeutic potential of muscarinic modulators in psychiatry.

Saturday, 10 October 2026 | 13:20-14:40 CEST

ICM - International Congress Center Messe München | Room 14a



Leslie Citrome, MD, MPH CHAIR

Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Adjunct Professor of Psychiatry and Behavioral Sciences
Northwestern Feinberg School of Medicine
Chicago, Illinois



Robert Perneczky, MD, PhD, MBA

Chair of Translational Dementia Research (tenured)
Head of the Department of Geriatric Psychiatry
Managing Senior Physician
Department of Psychiatry and Psychotherapy
Ludwig-Maximilians-Universität München
Munich, Germany



Silvana Galderisi, MD, PhD

Honorary Professor of Psychiatry
University of Campania Luigi Vanvitelli
Naples, Italy

Speakers are paid consultants of Bristol Myers Squibb

Please visit the exhibition stand of BMS (B0.06) for more information.